Gamco Investors INC. ET AL decreased its holdings in Akorn, Inc. (NASDAQ:AKRX) by 0.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 274,235 shares of the company’s stock after selling 2,590 shares during the quarter. Gamco Investors INC. ET AL owned 0.22% of Akorn worth $9,102,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of AKRX. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Akorn by 22.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,228 shares of the company’s stock worth $108,000 after purchasing an additional 599 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Akorn by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,177 shares of the company’s stock valued at $140,000 after buying an additional 626 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Akorn in the 2nd quarter valued at $209,000. World Asset Management Inc acquired a new stake in shares of Akorn in the 2nd quarter valued at $210,000. Finally, Suntrust Banks Inc. acquired a new stake in shares of Akorn in the 2nd quarter valued at $234,000. Hedge funds and other institutional investors own 68.72% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/gamco-investors-inc-et-al-sells-2590-shares-of-akorn-inc-akrx/1695737.html.

Akorn, Inc. (AKRX) opened at $33.21 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 3.17 and a current ratio of 4.16. Akorn, Inc. has a 1 year low of $17.61 and a 1 year high of $34.00. The company has a market cap of $4,146.09, a PE ratio of 20.59, a P/E/G ratio of 1.97 and a beta of 1.33.

AKRX has been the subject of a number of research analyst reports. Jefferies Group LLC reissued a “hold” rating and set a $34.00 target price on shares of Akorn in a research report on Wednesday, July 19th. BidaskClub cut shares of Akorn from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Royal Bank Of Canada set a $34.00 price target on shares of Akorn and gave the company a “hold” rating in a research report on Sunday, July 30th. TheStreet lowered shares of Akorn from a “b-” rating to a “c” rating in a research report on Tuesday, August 1st. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $34.00 target price on shares of Akorn in a research report on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. Akorn presently has a consensus rating of “Hold” and a consensus price target of $29.38.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Institutional Ownership by Quarter for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.